This renewal application requests funding for the 25th through 29th years of the NCI Cancer Center Support Grant of the City of Hope Comprehensive Cancer Center. The Center now has five research programs: one basic research Program (Cancer Biology, CB);three clinical/translational research Programs (Developmental Cancer Therapeutics, DCT;Cancer Immunotherapeutics, Cl;Hematologic Malignancies, HM);and one population research program (Cancer Control and Population Sciences, CCPS). Twelve shared resources support the scientific activities of the members, including two new cores (Small Animal Imaging;Clinical Immunobiology Correlative Studies Laboratory). Three developing cores are proposed (High Throughput Screening;Synthetic &Biopolymer Chemistry;Survey Research). Membership has grown by 45% in the preceding program period with the recruitment of 37 new Full Members, including several key senior leaders (Richard Jove, PhD, Deputy Director;R. Figlin, MD, Associate Director [AD] for Clinical Research). Other key leadership positions have also been filled through internal appointments (Smita Bhatia, MD, MPH, AD for Population Research;Joyce Niland, PhD, AD for Information Sciences;and Yun Yen, MD, PhD, AD for Translational Research). As a result of our program restructuring, recruitment and infrastructure development, we now believe we have a Center where our five Programs represent a continuum in which basic and translational studies in the basic science Program, CB, and one clinical Program, DCT, can be linked to Phase I and II clinical protocols in all three clinical programs (DCT, Cl, HM) and follow-up studies in survivorship and symptom management in the population sciences program (CCPS). All these activities are made possible by a Center and Institutional infrastructure that supports basic and translational research in biological and, now, small molecule approaches to cancer in an extraordinarily collaborative fashion. Such interaction has resulted in the Center's first SPORE, in lymphoma;a recent W.M. Keck Foundation award;and the renewal of eight large, multi-investigator awards. During the next funding period, we will build on these achievements so that the City of Hope Comprehensive Cancer Center takes the next step in its evolution: translating more laboratory discoveries into innovative clinical trials and developing disease-based research programs. The 82 Full Members and 90 Associate Members of the Center Programs have published 1001 articles, book chapters, etc., since the last competitive grant review. Of these, 28% are intraprogrammatic and 22% are interprogrammatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-29
Application #
8209208
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-08-01
Project End
2013-04-24
Budget Start
2011-12-01
Budget End
2013-04-24
Support Year
29
Fiscal Year
2012
Total Cost
$2,225,352
Indirect Cost
$884,778
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Wu, Chenkai; Ashing, Kimlin Tam; Jones, Veronica C et al. (2018) The association of neighborhood context with health outcomes among ethnic minority breast cancer survivors. J Behav Med 41:52-61
Wussow, Felix; Chiuppesi, Flavia; Meng, Zhuo et al. (2018) Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods 251:30-37
Wildes, Tanya M; Maggiore, Ronald J; Tew, William P et al. (2018) Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Support Care Cancer 26:3563-3570
Paz, Helicia; Joo, Eun Ji; Chou, Chih-Hsing et al. (2018) Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008. J Exp Clin Cancer Res 37:67
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2018) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer 17:235-245
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141

Showing the most recent 10 out of 1396 publications